NCT01259323已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Extrinsic Atopic Dermatitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 10
- 主要终点
- The primary endpoint in the study is the incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN668 or Placebo from baseline through week 12.
研究概览
简要总结
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of atopic dermatitis that has been present for at least 3 years before the screening visit
- •Investigator's Global Assessment (IGA) score of >/= 3 at the screening and baseline visits
- •>/= 15% body surface area (BSA) of AD involvement at the screening and baseline visits
- •History of inadequate response to a stable (>/= 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit
- •Willing and able to comply with clinic visits and study-related procedures
- •Patient able to read and understand, and willing to sign the informed consent form
排除标准
- •A positive QuantiFERON® - TB (tuberculosis) Gold Test at the screening visit
- •Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C and/or positive Hepatitis B surface antigen (HBsAg), positive Hepatitis C antibody (HCV)
- •Treatment with an investigational drug within 8 weeks before the baseline visit
- •Treatment with leukotriene inhibitors within 4 weeks before the baseline visit
- •Treatment with systemic corticosteroids within 4 weeks before the baseline visit
- •Treatment with topical corticosteroids, tacrolimus, and/or pimecrolimus within 1 week before the baseline visit
- •Systemic treatment for AD with an immunosuppressive/immunomodulating substance within 4 weeks before the baseline visit
- •Chronic or acute infection requiring treatment
- •History of clinical parasite infection, other than treated trichomoniasis
- •History of malignancy within 5 years before the baseline visit
- •Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results
- •Pregnant or breast-feeding women
- •Unwilling to use adequate birth control, if of reproductive potential and sexually active
结局指标
主要结局
The primary endpoint in the study is the incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN668 or Placebo from baseline through week 12.
时间窗: 12 weeks
次要结局
- The secondary endpoint is to characterize PK profile of study drug REGN668 from baseline through week 12.(12 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy VolunteersHealthyNCT01015027Regeneron Pharmaceuticals48
已完成
1 期
Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01055899Regeneron Pharmaceuticals15
已完成
1 期
Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy VolunteersHealthyNCT01197391Regeneron Pharmaceuticals48
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy VolunteersHealthyNCT01484600Regeneron Pharmaceuticals36
已完成
1 期
Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy VolunteersHealthy VolunteersNCT01074372Regeneron Pharmaceuticals32